Freze

Quick links to important sections

Freze

Treatment option: Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Freze

Quick Facts

Property Description
Active Ingredient Acetaminophen and Tramadol Hydrochloride
Form Tablet (Oral Preparation)
Pharmacological Class Combination Analgesic (Opioid/Non-opioid Agent)
Common Use Management of moderate to moderately severe pain
Origin Synthetic

What Type of Analgesic is Freze?

Freze is a prescription-only medicine (POM) classified as a fixed-dose combination (FDC) analgesic that belongs to the centrally acting opioid/non-opioid agent pharmacological class. This synthetic drug is composed of two agents with complementary mechanisms. This dual approach means the medicine addresses pain through two distinct pathways simultaneously, a strategy that is clinically recognized for its effectiveness in managing pain levels that exceed the relief provided by simpler, single-agent options.


Composition and Form: The Fixed-Dose Combination

Freze is comprised of two distinct active ingredients: the non-opioid pain reliever Acetaminophen (paracetamol) and the opioid agent Tramadol Hydrochloride. This preparation is most commonly supplied as an oral preparation in the form of a tablet, which is the standard dosage form for this fixed-dose combination. The use of a combination product provides significantly enhanced pain relief compared to the individual components alone. This clinical data indicates that combining the two substances offers a more effective approach to easing discomfort. Differentiation is often seen in the availability of immediate-release versus extended-release formulations, giving choices based on the required duration of effect.


General Purpose: Targeting Moderate to Moderately Severe Pain

The general therapeutic purpose of Freze is to manage moderate to moderately severe pain in adults when alternative pain treatments, such as simple analgesics, have not provided sufficient relief. This includes situations where a strong and predictable analgesic effect is needed. By combining the actions of Acetaminophen and Tramadol Hydrochloride, the medication achieves a synergistic effect that leverages both central and peripheral actions against pain signals. This synergistic design makes the combination a specialized choice for addressing discomfort that requires a more robust and multifaceted analgesic intervention.

What side effects are possible with Freze?

Possible Side Effects and Safety Information

The official safety profile for Freze, a combination of Acetaminophen and Tramadol Hydrochloride, is derived from government regulatory documents, including FDA and EMA labeling, and is classified by frequency and affected organ system. The most commonly reported adverse reactions involve the Nervous System and Gastrointestinal Tract.


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their incidence in clinical studies:

  • Very Common (≥ 10%): Nausea, Dizziness, Somnolence (sleepiness).
  • Common (1% to < 10%): Headache, Vomiting, Constipation, Dry mouth, Diarrhea, Insomnia, Sweating, Pruritus (itching).

Serious Adverse Reactions

The regulatory label highlights critical safety concerns related to both active components. These include the risk of life-threatening respiratory depression and the potential for hepatotoxicity (serious liver damage) associated with the acetaminophen content. Other documented serious risks are Serotonin Syndrome, seizures (convulsions), and Neonatal Opioid Withdrawal Syndrome if used for a prolonged period during pregnancy.


Population-Specific Safety Considerations

The medicine is officially contraindicated in children younger than 12 years of age and in patients with severe hepatic (liver) impairment. Use is generally not recommended in those with severe renal (kidney) impairment or during pregnancy and lactation. Official documents also note that older adults (aged 75 and over) may have an increased risk of Central Nervous System effects, such as dizziness.

Overdose and Emergency Response

This section outlines the officially documented overdose profile for Freze, a combination of Tramadol and Acetaminophen, based on regulatory labeling.

Documented Overdose Presentations

Overdose manifestations relate to toxicity from both components. Signs of Tramadol overdose include miosis (pinpoint pupils), convulsions, somnolence, and consciousness disorders up to coma. Acetaminophen toxicity may present initially with pallor, nausea, vomiting, and abdominal pain, followed by delayed signs of liver damage (hepatic failure) or acute renal failure.

Life-Threatening Outcomes

Regulatory documents highlight the risk of severe, life-threatening outcomes, including respiratory depression up to respiratory arrest, cardiovascular collapse, and Serotonin Syndrome. These severe outcomes contribute to the risk of fatal overdose, particularly following accidental ingestion by children.

Required Emergency Action

Immediate medical attention is critical in all cases of suspected overdose, even if no symptoms are immediately noticeable. Regulators instruct patients to seek emergency medical help at once or contact a Poison Control Center. Management involves maintaining vital functions and utilizing Naloxone to address the opioid component and repeated hepatic tests to monitor for liver damage.

Therapeutic Uses of Freze

What Freze Treats: Main Uses and Benefits

The combination is commonly used across conditions presenting with acute episodes that require additional management of discomfort. Freze is relevant for easing moderate to moderately severe pain symptoms in adult patients.

This analgesic is commonly applied in scenarios where additional management of discomfort is required, such as during the short-term relief of postoperative pain, management of acute musculoskeletal strain, or control of flares associated with chronic conditions like osteoarthritis and chronic low back pain. The medication is relevant for easing symptoms that are challenging to manage with initial symptomatic support.

When symptoms become more noticeable, this combination may assist with a reliable approach to symptomatic relief, which helps improve day-to-day comfort during symptomatic periods. This supportive benefit is crucial for patients needing to cope more steadily with temporary periods of heightened discomfort.


Quick Fact: Relief for Moderate to Moderately Severe Pain

Therapeutic Focus Symptom Level Key Benefit
Acute Episodes Moderate to Moderately Severe Helps ease the overall symptom burden
Refractory Discomfort Persistent, Untreated Pain Supports general well-being during symptomatic phases

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

The use of Acetaminophen and Tramadol Hydrochloride (Freze) is strictly defined by regulatory eligibility criteria, primarily for adults and adolescents 12 years and older whose pain is classified as moderate to moderately severe.


Eligibility Scope

Classification Official Regulatory Statements
Populations Allowed Adults and adolescents 12 years and older.
Populations Not Recommended Patients with severe renal impairment (creatinine clearance <10 mL/min) or severe respiratory impairment; breastfeeding women.
Populations Contraindicated Children younger than 12 years; children under 18 for post-tonsillectomy/adenoidectomy pain; severe hepatic impairment; acute intoxication with alcohol, opioids, or psychotropic drugs; patients taking MAOIs; uncontrolled epilepsy; known gastrointestinal obstruction.

Age- and Condition-Specific Eligibility

Age-related eligibility rules: Contraindicated for all children younger than 12 years. Use should be avoided in adolescents 12 to 18 years with respiratory risk factors. Older adults require cautious dose selection.

Condition-specific eligibility rules: Severe hepatic impairment is a formal contraindication. Severe renal impairment means use is not recommended. Patients prone to seizures should be treated only under compelling circumstances.

Pregnancy and lactation eligibility status: The medicine should not be used during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome. Use is not recommended during lactation.


Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use the medicine by classifying certain populations as contraindicated (e.g., severe hepatic impairment, children under 12) or not recommended (e.g., severe renal impairment, breastfeeding). This structure formally excludes populations where the risks are deemed unacceptable by governmental authorities.

What should I know about interactions with other medicines?

The official interaction profile for this medicine is characterized by specific prohibitions and a defined risk of adverse effects stemming from both additive pharmacological actions and metabolic interference.

Formal Prohibitions and Timing Rules: Concurrent use with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated, and a mandatory 14-day washout period must be observed after stopping an MAOI. Co-administration with any other medicinal product containing acetaminophen or tramadol is strictly prohibited to avoid exceeding the maximum daily dosage and mitigate the risk of toxicity.

High-Risk Pharmacodynamic Interactions: Co-administration with Central Nervous System (CNS) depressants, including alcohol and benzodiazepines, carries a documented risk of additive effects, potentially leading to profound sedation and severe respiratory depression. Concomitant use with agents that affect serotonin levels, such as certain antidepressants, officially increases the risk of Serotonin Syndrome. Furthermore, use with Mixed Opioid Agonist/Antagonists is documented as potentially reducing the analgesic effect or causing withdrawal symptoms.

Metabolic and Clearance Interactions: The official exposure profile is affected by inhibitors and inducers of the CYP2D6 and CYP3A4 enzymes. CYP2D6 Inhibitors, for instance, may increase the parent drug concentration, while CYP3A4 Inducers, such as Carbamazepine, may reduce overall drug exposure. The drug is officially not recommended for use in patients with severe hepatic impairment due to clearance concerns, and CYP2D6 Ultra-Rapid Metabolizers are noted to have an increased risk of specific adverse effects.

Mechanism of Action

How Freze Works: Dual-Domain Central Mechanism

Freze employs a fixed-dose combination to modulate nociceptive signaling by simultaneously targeting two distinct, complementary domains within the central nervous system (CNS).


Opioid Receptor Gating and Signal Suppression

This mechanism involves the primary action of the active Tramadol metabolite ( M1), which functions as an agonist at the mu-Opioid Receptor (mu-OR) to modulate nociceptive signaling. By engaging these receptors, the drug initiates a cascade that decreases neuronal excitability, reducing the presynaptic release of excitatory neurotransmitters. This action limits the propagation of signals ascending to the brain.


Monoamine Augmentation and Endogenous Pathway Enhancement

A separate but supporting mechanism involves the parent Tramadol compound's ability to act as a reuptake inhibitor for the neurotransmitters Norepinephrine and Serotonin. This action increases the synaptic concentration of these chemicals, which, in turn, enhances the activity of the descending inhibitory pathways, contributing to the central regulation of nociceptive input.


Non-Opioid Modulation of Central Sensitization

The Acetaminophen component contributes to the overall effect through a distinct mechanism focused on central sensitization. It inhibits Cyclooxygenase (COX) enzyme activity predominantly in the brain and spinal cord, thereby reducing the synthesis of pro-nociceptive Prostaglandins ( PGE2). This physiological adjustment contributes to the modulation of nociceptive threshold by limiting the chemical mediators that contribute to central neuronal sensitization.

Dosage and Administration Information

How Freze is Used

Freze is approved for oral administration only, supplied as a fixed-dose combination tablet containing Acetaminophen and Tramadol Hydrochloride. Its application is strictly limited to short-term periods, generally for five days or less, for acute symptom management.

The administration follows a structured, as-needed (PRN) schedule. The standard adult starting dose is two tablets of the 37.5 mg/325 mg strength. This dose may be repeated every 4 to 6 hours as required for symptom relief. Crucially, a strict minimum interval of six hours must be maintained between any two doses, and the total intake must not exceed eight tablets in a 24-hour period. This dosing is designed to manage symptomatic periods while preventing accumulation of the active agents.

Administration Constraints and Adjustments

Specific Condition Official Usage Instruction
Ingestion May be taken with or without food. Tablets must be swallowed whole; they should not be crushed, broken, or chewed.
Duration Use is limited to the shortest time necessary, not exceeding five days.
Severe Renal Impairment The maximum allowable dose is reduced to two tablets every 12 hours.
Severe Hepatic Impairment Use is not recommended in this population.
Older Adults (>75 years) The minimum dosing interval should be extended to six hours or more due to slower drug elimination.

This official regimen dictates a precise, intermittent method for administration that incorporates mandatory dose adjustments for specific physiological conditions, ensuring use strictly adheres to established limits.

Recent Clinical Evidence

Research examining the combination for acute pain involves short-term, randomized controlled trials (RCTs). These studies focused on adult populations, primarily monitoring changes in pain intensity scores and the time to onset of change over a brief treatment period. For chronic conditions, such as osteoarthritis and chronic low back pain (LBP), research has explored the combination in intermediate-term studies, typically lasting up to three months. These trials monitored functional status using specific indices and average daily pain scores. Research has also explored the combination for painful diabetic peripheral neuropathy (DPN), focusing on changes in pain and sleep quality.

The evidence base shows consistency across short-term acute pain trials, but evidence quality varies for chronic indications. A key limitation across all studied conditions is the follow-up duration. Most pivotal studies track outcomes only up to three months, meaning long-term effects on functional status and sustained patterns of use are not fully established. Limited comparative evidence is also lacking against other alternative pain management strategies.

While studies included older adults, specific evidence describing the outcomes in frail or very elderly populations and for people who are pregnant remains insufficient. Research highlights what is known—and what is still uncertain—about the combination, emphasizing areas where more data is needed.

Key Studies & References

  1. Tramadol for the Management of Pain in Adult Patients: A Review of Clinical Effectiveness — An Update (CADTH Report)
  2. Tramadol hydrochloride/acetaminophen combination for the relief of acute pain

Frequently Asked Questions (FAQ)

Common questions about Freze (FAQ)


Q: Why did my doctor prescribe Freze for this condition?

The official indication for this medicine is the management of moderate to moderately severe pain when relief is not sufficiently achieved by alternative treatments. Regulatory documents confirm its approved use is limited to short-term periods, typically for five days or less.

This is the condition and context for which its use is officially indicated by government authorities.


Q: How is Freze different from similar treatments?

According to the official product information, Freze is defined as a fixed-dose combination (FDC) analgesic, meaning it contains two active ingredients that work simultaneously. Regulatory documents describe its action as targeting pain signals via two distinct, complementary central pathways. This dual approach distinguishes it from simpler, single-agent options.


Q: How soon after starting Freze will I notice a change?

Clinical studies documented for regulatory review indicate that the medicine typically begins to provide pain relief within 30 minutes of taking a dose. The effects usually reach their peak approximately 1 to 2 hours after administration.


Q: What happens if I forget to take Freze?

Regulatory guidelines define the administration schedule as being on an as-needed (PRN) basis. The official safety limits require that a minimum interval of six hours be maintained between any two doses to help prevent the accumulation of the active ingredients.


Q: Does Freze interact with common over-the-counter medications?

Official warnings state that co-administration with any other product containing acetaminophen or tramadol is formally prohibited. This regulatory prohibition includes certain common over-the-counter medications, as exceeding the maximum daily dosage of these ingredients can pose a risk of toxicity.


Q: Are there any foods or drinks to avoid with Freze?

The official label states that the tablets may be taken with or without food. However, regulatory warnings explicitly note a risk of serious additive effects, including profound sedation and respiratory depression, when consuming alcohol.


Q: What does 'contraindication' mean regarding Freze?

In the context of the official labeling, a contraindication is a condition or situation where the use of the medicine is formally prohibited. This prohibition exists because regulatory authorities have determined the risks are considered to outweigh any potential benefits for individuals with that specific condition.


Q: Do you need to stop Freze gradually?

Official regulatory documents address the procedure for stopping the medicine. The process often involves the gradual reduction of the dosage, usually over several days, to help mitigate the risk of experiencing withdrawal symptoms.


Q: What should I do if a side effect seems serious?

Official safety information includes warnings about serious adverse reactions, such as life-threatening respiratory depression, seizures, and severe liver damage. Regulatory documents state that serious reactions, such as those listed, require immediate medical assessment.


Q: Can Freze affect my ability to drive?

Official safety information includes warnings that the medicine may cause dizziness or somnolence (sleepiness) due to its Central Nervous System (CNS) effects. Regulatory warnings indicate that these effects may affect the ability to perform tasks that require concentration or coordination, such as driving.


Q: Is Freze known to cause allergic reactions?

Regulatory documents state that the medicine is formally contraindicated in patients with a known history of hypersensitivity or allergic reaction to either acetaminophen, tramadol, or any other component of the formulation.


Q: How does Freze leave the body?

After being processed (metabolized) by liver enzymes, the regulatory profile indicates the medicine's components and their breakdown products (metabolites) are primarily eliminated from the body via the kidneys (renal excretion).


Q: What is the difference between Freze and a placebo in studies?

Regulatory documents covering clinical studies indicate that the combination product provided statistically significant relief compared to a placebo (an inactive substance) in short-term trials. The benefit was typically measured by assessing changes in pain intensity scores among patients.


Q: Can I take Freze if I have a history of heart issues?

Official regulatory documents do not list a history of heart issues or cardiac disease as a formal contraindication for use. Eligibility rules are primarily focused on conditions like severe hepatic or renal impairment, and existing drug interactions.


Q: Are there specific tests I need before starting Freze?

Official regulatory warnings highlight concerns for patients with severe hepatic (liver) and renal (kidney) impairment, and those whose bodies process the medicine rapidly (CYP2D6 ultra-rapid metabolizers). This suggests that an official assessment of these conditions may be needed before administration.


Q: Is it possible for Freze to stop working after a while?

Official labels include warnings regarding the potential for physical and psychological dependence with repeated use. This potential can involve tolerance, which is the body's decreased response to the original dose over time.


Q: What is the most frequently reported side effect in studies for Freze?

According to official regulatory documents, the most frequently reported adverse reactions occurring in 10% or more of studied patients (classified as Very Common) are Nausea, Dizziness, and Somnolence (sleepiness).


Q: Is it normal if I don't feel any difference after a week of Freze?

Official regulatory approval limits the use of this medicine to a short-term period of five days or less. When relief is not experienced within the expected timeframe, regulatory guidance indicates that a review of the treatment plan is necessary.


Q: Is Freze safe to take with common pain relievers like ibuprofen?

Regulatory documents prohibit co-administration with any product containing acetaminophen. However, there are no formal contraindications regarding non-acetaminophen, non-opioid pain relievers such as ibuprofen in the official documentation.


Q: Can Freze cause mood changes?

The official safety profile includes common adverse effects like insomnia and somnolence. Official warnings also address the risk of Serotonin Syndrome, which may involve changes in mental status, mood, or behavior.


Q: What percentage of people experience side effects with Freze?

The safety profile classifies adverse effects by frequency, grouping them into categories like Very Common (reported by 10% or more of patients) and Common (reported by 1% to less than 10% of patients). An overall incidence rate covering all side effects is not typically provided in this classification format.


Q: What is the typical age range of people who use Freze?

Regulatory documents state the medicine is approved for use in adults and adolescents 12 years and older. The clinical evidence base primarily involves adult patient populations, though cautious use is noted for older adults (aged 75 and over).


Q: Can Freze be used by people with diabetes?

Research evidence has explored the combination product for painful diabetic peripheral neuropathy (DPN). Regulatory eligibility criteria do not list diabetes itself as a formal contraindication for use.

How should Freze be stored and disposed of?

How to Store and Dispose of Freze?

The storage and disposal of Freze (tramadol hydrochloride/acetaminophen) must strictly adhere to regulatory requirements to ensure product integrity and public safety, given its classification as a controlled substance.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Brief excursions up to 30 C are permitted.
Protection Keep from freezing and store away from heat, moisture, and direct light.
Child Safety Due to the risk of accidental overdose, the medicine must be stored in a closed container and kept out of the sight and reach of children in a secure location.

Official Disposal

Disposal protocols are designed to prevent misuse. Unused or expired Freze must be discarded immediately using an authorized drug take-back program or a DEA-registered collector. If these options are unavailable, regulatory guidance permits mixing the tablets with an unappealing substance, sealing the mixture, and discarding it in the household trash. It must not be flushed or thrown into household waste without preparation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Freze found in:

A-Z Index: